Inozyme: Positive Topline Data from Ongoing Phase 1/2 Trials of Vessel Disorder Med

 Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial -

- Rapid and significant increase in PPi observed in all dose cohorts with sustained increase observed in highest dose cohort in ABCC6 Deficiency (PXE) trial -

- INZ-701 was generally well-tolerated and exhibited a favorable safety profile in both trials -

- Company updates its cash runway guidance to fund cash flow requirements into fourth quarter of 2024 -

- Company to host virtual investor and analyst event at 8:00 a.m. ET on February 16, 2023 -

The Company will host an Investor and Analyst Event today, Thursday, February 16, 2023, at 8:00 a.m. ET to present the topline results from the trials in greater detail as well as provide an overview of the opportunity and planned development milestones in each indication. Joining the call will be members of the Inozyme management team as well as the following key opinion leaders:

• Michael A. Levine, M.D., Professor Emeritus, Pediatrics and Medicine and Chief Emeritus, Division of Endocrinology and Diabetes at the Center for Bone Health at the Children’s Hospital of Philadelphia Research Institute

• Wilko Spiering, M.D., Ph.D., Associate Professor, Division of Internal Medicine and Dermatology, Department of Vascular Medicine, at the University Medical Center Utrecht of Utrecht University

• Mark Kiel, M.D., Ph.D., Founder and Chief Science Officer of Genomenon
  

The live webcast and replay will be accessible here and through Inozyme’s website under News and Events. Alternatively, the conference call may be accessed by dialing:

• Domestic Dial-in Number: 1-877-317-6789

• International Dial-in Number: 1-412-317-6789

• Participants should ask to be joined into the Inozyme Pharma call.

https://finance.yahoo.com/news/inozyme-pharma-reports-positive-topline-123000984.html